CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY (EBMT 2026) - Mar 14, 2026 - Abstract #B101; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Since 2017, letermovir (LMV) prophylaxis is recommended after alloHSCT in R+ to decrease the incidence of clinically significant CMV infection (CS-CMVi)...First line pre-emptive treatment was given for a median of 23 days (min: 15, max: 68) and was ganciclovir in 23/24 patients (96%). Eight patients (33.3%) needed second-line foscarnet treatment due to cytopenia (n= 7) or virological failure (n= 1)... In our cohort, the incidence of positive CMV PCR in D+/R- alloHSCT patients was lower than historically reported. LMV significantly reduced the incidence of CMV PCR positivity, and was associated with a trend towards a significant reduction in the incidence of CS-CMVi, maybe due to the small size of the cohort. TBI was the only factor significantly associated with a CMV PCR positivity."
Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation
|
|
Constance Fournier1; Mathilde Ruggiu-Goirand1; Marie Robin1; Flore Sicre de Fontbrune1; David Michonneau1; Clara Caillon1; Matthieu Jestin1; Florian Chevillon1; Nathalie Dhedin1; Regis Peffault de Latour1; Jerome Le Goff1; Alienor Xhaard1
|